Crucell 2009 Annual General Meeting of Shareholders 2008 Financial
Statements Adopted; All Resolutions Approved
Leiden, The Netherlands (June 5, 2009) - Dutch biopharmaceutical
company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)
today announced that the Annual General Meeting of Shareholders (AGM)
held today in Leiden adopted the 2008 financial statements. In
addition, the AGM reappointed Mr. P. Satow and Mr. A. Hoevenaars as
members of the Supervisory Board; Mr. Floris Waller was appointed as
a new member of the Supervisory Board.
The shareholders of Crucell were represented in person, by proxy
voting, or by voting instruction, representing a total of 27% of the
total issued share capital entitled to vote.
The shareholders approved the appointment of Mr. Floris Waller as a
member of the Supervisory Board. The appointment is for a term of
four years, until 2013. Other members of the Supervisory Board, Mr.
Philip Satow and Mr. Arnold Hoevenaars, were reappointed for a term
of four years by Crucell's shareholders.
Furthermore the AGM approved the 2008 financial statements and all
other resolutions.
At the meeting, presided by Jan Oosterveld, Chairman of the
Supervisory Board, Ronald Brus, CEO of Crucell and Leon Kruimer, CFO
discussed the company's 2008 results, reiterated the outlook for 2009
[1], and presented their views on the business and strategy of the
company to shareholders. The slides of the presentation given at the
AGM are available on the company's website www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on April
22, 2009, in the section entitled 'Risk Factors'. The Company
prepares its financial statements under International Financial
Reporting Standards (IFRS).
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
global biopharmaceutical company focused on research development,
production and marketing of vaccines, proteins and antibodies that
prevent and/or treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio
includes a vaccine against hepatitis B, a fully-liquid vaccine
against five important childhood diseases and a virosome-adjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such
as the only oral anti-typhoid vaccine, an oral cholera vaccine and
the only aluminum-free hepatitis A vaccine on the market. The Company
has a broad development pipeline, with several product candidates
based on its unique PER.C6® production technology. The Company
licenses its PER.C6® technology and other technologies to the
biopharmaceutical industry. Important partners and licensees include
DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &
Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the U.S.
The Company employs over 1000 people. For more information, please
visit www.crucell.com.
For further information please contact:
Crucell N.V.
Oya Yavuz
Vice President
Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
ir@crucell.com
www.crucell.com
[1] Total revenues and other operating income expected to grow 20% in
constant currencies (Guidance currency = EUR/USD rate of 1.35);
operating profit for 2009 expected to improve significantly compared
to 2008; solid cash flow.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.